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Abstract: Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes
inflammation of the large intestine and affects approximately 7.6–24.6 per 100,000 persons.
The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally,
obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in
May 2014 for the treatment of moderate-to-severe UC and Crohn’s disease, is a newly developed
anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and
data from early trials, and details the results of the landmark trails that led to its approval in
the USA with a specific focus on the management of UC. Additionally, data on safety and the
current UC management protocols are also discussed.
Keywords: inflammation, mucosal healing, remission, immunomodulator drugs, infliximab,
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The incidence of ulcerative colitis (UC) ranges from 1.2 to 20.3 cases per
100,000 person-years, and prevalence ranges from 7.6 to 24.6 per 100,000 persons.1
Approximately 50% of patients present with proctosigmoiditis, 30% with left-sided
colitis, and 20% with pancolitis, and approximately 50% progress to more extensive
disease over the first 5 years of disease.2 UC is characterized by recurring episodes of
inflammation of the mucosal layer and is limited to the colon.
The therapeutic goal for UC patients is not only achieving symptomatic relief
(induction of remission) but also to obtain mucosal healing. Thereafter, the goal is to
prevent disease flares (maintenance of remission).
The treatment options for UC consist of sulfasalazine, 5-aminosalicylic acid
(5-ASA), corticosteroids, immunomodulator drugs (azathioprine, 6-mercaptopurine),
calcineurin inhibitors (cyclosporine and tacrolimus), anti-tumor necrosis factor (TNF)alpha antibodies (infliximab [IFX], adalimumab, golimumab), and an integrin antagonist
(vedolizumab). Introduction of anti-TNF agents in the last decade has revolutionized
the care of UC patients and management of moderate-to-severe UC. The ACT 1 and
ACT 2 trials demonstrated the efficacy of IFX in the induction and maintenance of
moderate-to-severe UC. Treatment with IFX has shown nearly a 60%–70% response
rate in UC, but up to 40% are primary nonresponders, and 10% per year develop
secondary nonresponse to IFX therapy.3–5 While primary nonresponse may be due to
proinflammatory pathways that bypass TNF-alpha, secondary nonresponse has been
correlated with the development of antidrug antibodies, accelerated drug clearance,
albumin concentration, and degree of systemic inflammation.6 Additionally, response
to a second anti-TNF is lower than in anti-TNF-naïve patients.4
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The efficacy and safety of vedolizumab in the induction
and maintenance of UC were established in the GEMINI 1
study.7 This antibody, unlike natalizumab, does not penetrate
the blood–brain barrier and therefore avoids immunomodulation of T-cell trafficking to the central nervous system. Vedolizumab received US Food and Drug Administration approval
in May 2014 for the treatment of moderate-to-severe Crohn’s
disease (CD) and UC.8 The most recent treatment algorithms
highlighted by the American College of Gastroenterology,
last published in 2010, predate the development of vedolizumab. The European Crohn’s and Colitis Organization’s
ulcerative management guidelines (https://www.ecco-ibd.
eu/images/6_Publication/6_3_ECCO%20Guidelines/2012_
UC_Cosensus_Update_2_Current_Management.pdf) date to
2012 and do acknowledge vedolizumab but do not specifically
describe the role of vedolizumab. In the most recent guidelines
published by the American Gastroenterological Association,
The Toronto Consensus, with regard to the nonhospitalized
UC patient, vedolizumab is recommended for those with primary failure to anti-TNF therapy and as an equivalent option
to a second anti-TNF agent in those with secondary failure
to anti-TNF.9 Others have suggested that for induction and
maintenance of moderate-to-severe UC, anti-TNF agents and
anti-integrin agents are similarly positioned.10

Review of pharmacology, mode of
action, and pharmacokinetics of
vedolizumab
Vedolizumab (Entyvio), produced by Takeda Pharmaceuticals, evolved as is a humanized monoclonal antibody (IgG1),
composed of two light chains of the kappa subclass and two
IgG1 heavy chains, whose action is to selectively bind to
integrin α4β7, and modulates gut lymphocyte trafficking.
Vedolizumab blocks the interaction of α4β7 integrin, a
cell surface glycoprotein variably found on T-lymphocytes,
with cell adhesion modules (MAdCAM-1, VCAM-1, and
fibronectin) expressed on gut endothelial cells and thereby
inhibits the infiltration of T-lymphocytes into inflamed
gastrointestinal tissue. 3,8,11 This allows vedolizumab to
provide more specific anti-inflammatory activity while
avoiding central nervous system toxicity which has limited
the acceptance of the first anti-integrin therapy approved
for treatment of CD, natalizumab. In a study of 14 healthy
subjects, vedolizumab did not affect the CD4+ lymphocyte
cell counts, CD8+ lymphocyte cell counts, or the CD4+:CD8+
ratios in the cerebrospinal fluid.12
In a placebo-controlled study, healthy volunteers
received vedolizumab or placebo followed by intramuscular
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vaccination with hepatitis B vaccine and with oral cholera
vaccine. Those treated with vedolizumab did not have lower
rates of protective immunity to hepatitis B but did have lower
cholera titers, which speaks to the gut specificity of the effect
of vedolizumab.13
Phase II studies of pharmacokinetics suggest that vedolizumab exhibits dose-proportional pharmacokinetics, and
at a minimal dose of 2 mg/kg, there is maximal saturation
of α4β7 receptors found on peripheral serum lymphocytes.
The mean elimination half-life of vedolizumab is 15–22 days,
with detectable steady levels of the drug at one infusion every
8 weeks (q8wk), after initial induction at 0 week, 2 weeks,
and 6 weeks.6 The clearance of vedolizumab conformed to
a standard linear model over a broad range of body weights,
so a fixed dose has been recommended.
Pharmacokinetics of vedolizumab in patients with renal
or hepatic insufficiency has not been studied.

The refinement process which led
to vedolizumab
Vedolizumab was the end result of an evolutionary process
that included precursor antibodies, LDP-02, MLN-02, and
MLN-0002.
The first Phase I/II trial of α4β7 integrin inhibitor
(LDP-02) was a double-blind, placebo-controlled study of 29
patients with moderate-to-severe UC. The trial assessed the
clinical and endoscopic effect of an infusion of single escalating dose (0.15 mg/kg subcutaneous, 0.15 mg/kg intravenous
[IV], 0.5 mg/kg IV, 2.0 mg/kg IV) of LDP-02 at 30 days.
An IV dose of 0.5 mg/kg was found to completely saturate
antibody receptors. Complete endoscopic (Baron grade =0)
and clinical remission (Mayo score =0) was found in 40%
of patients at an optimal dose of 0.5 mg/kg. Headache was
the only reported side effect in this study.14 A drug modification was sought subsequently to develop a more humanized
antibody, as described below.
A Phase II trial using α4β7 antibody derived from the
NS0 mouse myeloma cell line (MLN-02, more humanized
light chain than the light chain of LDP-02) was a multicenter, double-blind, placebo-controlled trial in 181 patients
with active UC. Patients were randomized to three groups
(placebo, 0.5 mg/kg, and 2.0 mg/kg), and each patient
received two infusions (on days 1 and 29). Patients were
followed for 6 weeks with sigmoidoscopy performed at
baseline and at weeks 4 and 6. The primary outcome was
clinical remission at week 6 (defined as Mayo score 0–1
without rectal bleeding and Baron grade 0–1). The results
demonstrated clinical remission in 14% of patients in the
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placebo group, 32% in the 2.0 mg/kg group, and 33% in
the 0.5 mg/kg group (P=0.03). The secondary outcome was
clinical improvement by at least 3 points on the Mayo score.
This was seen in 33% of the patients in the placebo group,
66% in the 0.5 mg/kg group, and 53% in the 2.0 mg/kg
group. Endoscopic remission was seen in 8% of patients in
the placebo group, 12% in the 2.0 mg/kg group, and 28% in
the 0.5 mg/kg group (P=0.007).15 While these results were
encouraging, 44% of exposed patients developed detectable
human antihuman antibodies (HAHAs) at week 8. Among
the patients who developed immunogenicity/HAHAs, there
was faster clearance of the drug, more rapid loss of α4β7
receptor saturation, and subsequently a decrease in clinical
response.7
Additional work led to the development of a less immunogenic antibody, MLN-0002, using a Chinese hamster
ovary cell-based system.7,16 Only 11% of patients developed
HAHAs by week 8 with exposure to MLN-0002.17 In 2012,
Parikh et al performed a Phase II trial using the new formulation of the antibody, MLN-0002. This was performed
using escalating doses of MLN-0002 (2 mg/kg, 6 mg/kg,
and 10 mg/kg) versus placebo in patients with UC and CD.
Patients were included if they had clinical and endoscopic UC
for 2 years, Mayo score of 2–7, and were on stable doses
of other inflammatory bowel disease (IBD) medications.
Forty-seven patients from eleven centers were included in the
study, 2 mg/kg (n=13), 6 mg/kg (n=14), and 10 mg/kg (n=11),
and placebo (n=9). Patients received four infusions, one each
on days 1, 15, 29, and 85, and were followed for 253 days.
Primary outcomes were to study the clinical pharmacology
and safety of vedolizumab, and the secondary outcome was
to study clinical remission and response. Fecal calprotectin
was used as a surrogate marker for mucosal inflammation as
documented by the partial Mayo score (PMS).16
Secondary outcome of clinical response at the end
of induction (day 43) was seen in 51% of patients in the
MLN-0002 group and 13% in the placebo group. From days
29–253, the all-severity (PMS 0–9) vedolizumab responders
were 50% versus 22%–33% in the placebo group, while the
percentage of responders was highest in the 6 mg/kg group.
Over 50% of patients exposed to vedolizumab continued
to show clinical response over the full length of the trial.
Fecal calprotectin decreased from 405 μg/g to 54 μg/g in
the vedolizumab group and from 310 μg/g to 192 μg/g in
the placebo-treated group.16
MLN-0002 was moved to Phase III clinical trials as
vedolizumab, and we detail the seminal clinical study of UC
in the next section.
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Role of vedolizumab in induction
of remission in UC
GEMINI 1, a Phase III study of vedolizumab in UC patients,
was published in the New England Journal of Medicine in
2013 by Feagan et al. This was a randomized, double-blind,
placebo-controlled trial evaluating the efficacy of vedolizumab in inducing and maintaining remission in patients
with moderate-to-severe UC. Inclusion criteria were age of
18–80 years, Mayo score of 6–16, and endoscopic subscore
of at least 2 despite previous treatments with steroids, thiopurines, and/or anti-TNFs. Patients were allowed to take
current medications at stable doses (ie, mesalamine, prednisone 30 mg/day, and/or immunosuppressive agents) which
was permitted through week 6. Patients were ineligible if
they had anti-TNFs within 60 days, cyclosporine, or thalidomide within 30 days. The primary outcome of induction
therapy was clinical response at week 6 (reduction in Mayo
score of 3 points and 30% from baseline plus a decrease
in rectal bleeding subscore of 1 point or absolute rectal
bleeding subscore of 1 point). Secondary outcomes were
clinical remission (Mayo score 2 and no subscore higher
than 1) and mucosal healing (endoscopic subscore of 0 or
1) at week 6.7
For induction therapy (cohort 1), patients were randomized in 3:2 ratio to receive IV vedolizumab 300 mg (225
patients) or placebo (149 patients) at days 1 and 15 (with
or without use of glucocorticoids, with previous anti-TNF
exposure limited to 50%). In addition, another 521 patients
(cohort 2) received open-label vedolizumab for induction
therapy at days 1 and 15.5 In cohort 1, 47% of patients
receiving vedolizumab versus 25% of patients receiving
placebo had a clinical response, 16.9% versus 5.4% of
patients achieved clinical remission, and 40.1% versus 24.8%
achieved mucosal healing at week 6 follow-up. In cohort 2,
44% had clinical response, 19% had clinical remission, and
36.7% had mucosal healing, similar to cohort 1, suggesting
that no significant bias toward treatment was shown in the
open-label group (Table 1; data from cohort 1 only).7
A Cochrane analysis of four trials (606 patients) published recently confirmed the efficacy of vedolizumab
(included different versions of the antibody eventually named
vedolizumab; LDP-02, MLN-02, and MLN-0002) in induction of remission in UC compared to placebo. Seventy-seven
percentage (293/382) of patients who received one of these
formulations failed to achieve clinical remission compared to
92% (205/224) in the placebo group (relative risk [RR] 0.86,
95% confidence interval [CI] 0.80–0.91) after 4–6 weeks of
treatment. After week 6 (pooled analysis of three studies),
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Table 1 Proportion of patients meeting efficacy endpoints at week 6
Outcome

Placebo
(n=149)

Vedolizumab
(n=225)

P-value

Clinical response*
at week 6
Clinical remission#
at week 6
Improvement of endoscopic
appearance of the mucosa‡
at week 6

38 (25.5%)

106 (47.1%)

0.001

8 (5.4%)

38 (16.9%)

0.001

37 (24.8%)

92 (40.9%)

0.001

Notes: *Clinical response: reduction in complete Mayo score of 3 points
and 30% from baseline with an accompanying decrease in rectal bleeding
subscore of 1 point or absolute rectal bleeding subscore of 1 point. #Clinical
remission: complete Mayo score of 2 points and no individual subscore 1 point.
‡
Improvement in endoscopic appearance of the mucosa: Mayo endoscopy subscore
of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern, mild
friability).

48% of patients in treatment group failed to show clinical
response compared to 72% in placebo group (RR 0.68, 95%
CI 0.59–0.78). Sixty-eight percentage of patients in the treatment group failed to achieve endoscopic remission versus
81% of the placebo patients (RR 0.82, 95% CI 0.75–0.91).
These moderate- to high-quality studies suggest that vedolizumab is superior to placebo in induction of clinical
remission, clinical response, and endoscopic remission in
patients with UC.17

Role of vedolizumab in maintenance
of remission in UC
In GEMINI 1 study, only patients who had clinical response
at week 6 in cohort 1 and cohort 2 were randomly assigned
in a double-blind fashion (1:1:1) to one of the following regimens beginning at week 6: vedolizumab 300 mg q8wk (122
patients), vedolizumab 300 mg every 4 weeks (q4wk; 125
patients), or placebo q4wk (126 patients). Patients who did
not have a clinical response at 6 weeks received open-label
vedolizumab q4wk for up to 52 weeks. Primary outcome was

clinical remission at week 52, and secondary measures were
durable clinical response, durable clinical remission, mucosal
healing, and steroid-free remission at 52 weeks. Concomitant ASA and steroids were permitted through week 52;
however, concomitant immunomodulators were only permitted outside the USA.7
At week 52, 41.8% of patients receiving vedolizumab
q8wk and 44.8% of patients receiving vedolizumab q4wk
were in clinical remission, compared to 15.9% from the placebo group (P0.001). All of the secondary outcomes were
significantly higher among the vedolizumab groups compared to the placebo group. Additionally, concurrent treatment with steroids and/or thiopurines and previous therapy
with anti-TNF did not change efficacy of vedolizumab. There
was no significant difference between the two vedolizumab
regimens (Table 2).7
While these results may appear comparable to earlier
biologic therapies for UC, it should be clarified that the final
numbers were enriched by only allowing drug responders into
the maintenance arm. Hence, the interpretation of the maintenance results should be read as “41.8% of those enrolled
into the maintenance trail at q8wk dosing for vedolizumab,
which was 47% of the randomized induction population,
achieved clinical response at week 52.”
What happened to those who did not meet clinical
response at week 6 and were administered open-label vedolizumab q4wk? Currently, the data are available only in
abstract form and are combined with “early terminators” and
those who completed the 52-week maintenance trial and then
dose escalated to q4wk as part of the GEMINI LTS study,
to be completed in 2016. Two analyses were presented,
a prespecified analysis involving the efficacy population
(EP; GEMINI 1 completers) and a post hoc analysis involving observed cases (OCs; EP patients who had baseline
and 1 partial Mayo score post-baseline measurements).

Table 2 Proportion of patients meeting efficacy endpoints at week 52
Outcome

Placebo
(n=126)

Vedolizumab every
8 weeks (n=122)

Vedolizumab every
4 weeks (n=125)

P-value

Clinical remission at week 52
Durable clinical response*
Durable clinic remission#
Mucosal healing at week 52‡
Glucocorticoid-free remission‡‡

20 (15.9%)
30 (23.8%)
11 (8.7%)
25 (19.8%)
10 (13.9%)

51 (41.8%)
69 (56.6%)
25 (20.5%)
63 (51.6%)
22 (31.4%)

56 (44.8%)
65 (52.0%)
30 (24.0%)
70 (56.0%)
33 (17.6%)

0.001
0.001
0.008
0.001
0.01

Notes: Patients must have achieved clinical response at week 6 to continue into UC trial II. This group includes patients who were not in clinical remission at week 6. *Clinical
response: reduction in complete Mayo score of 3 points and 30% from baseline with an accompanying decrease in rectal bleeding subscore of 1 point or absolute
rectal bleeding subscore of 1 point at weeks 6 and 52. #Clinical remission: complete Mayo score of 2 points and no individual subscore 1 point at weeks 6 and 52.
‡
Improvement in endoscopic appearance of the mucosa: Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern, mild
friability). ‡‡Corticosteroid-free clinical remission: assessed in the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response at
week 6 (n=72 for placebo and n=70 for vedolizumab every 8 weeks). Corticosteroid-free clinical remission was defined as the proportion of patients in this subgroup who
discontinued corticosteroids by week 52 and the proportion of patients in clinical remission at week 52.
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Of the GEMINI completers who enrolled in GEMINI
LTS, 66% were in clinical remission at week 52, and 73%
were in clinical remission at week 104. Also, 79% had
clinical response at week 52, and 80% had clinical response
at week 104. At week 104, 65.3% (EP) and 79.5% (OCs)
of patients with prior biological failure had remission,
and 73.7% (EP) and 89.7% (OCs) had a response.18 In the
GEMINI 1 early terminators group, 31% and 19% had
clinical response, and 3% and 13% had clinical remission
at week 52 and week 108, respectively.19 While this data
suggest that a lack of response to induction therapy can
extrapolate to poor long-term response to vedolizumab, it
should be noted that the sample size in the early terminators
group was extremely small (only eight patients received
vedolizumab q4wk). However, given the heterogeneous
populations enrolled in this registry, the interpretation of
these data remains vague, though encouraging.
Additionally, another abstract from open-label findings
suggests that patients who lost response to dosing at q8wk
may have improvements in mean disease activity scores with
an increase in dosing frequency to q4wk without an apparent
increased risk of adverse events (AEs).18

Safety and tolerability
Vedolizumab is a very well-tolerated medication. The rates
of AEs in the vedolizumab group were similar to the placebo
group. A Cochrane meta-analysis of two studies found that
79% of patients in vedolizumab group and 80% of patients in
the placebo group experienced at least one AE (RR 0.99, 95%
CI 0.93–1.07). The pooled analysis of these two studies also
showed that the withdrawals due to AEs were significantly
lower in the vedolizumab group (6%) compared to placebo
(11%) (RR 0.55, 95% CI 0.35–0.87).2 The most common
infusion-related side effects include viral upper respiratory
tract infection symptoms, back pain, rash, and itching, which
occurred in 4% of those receiving vedolizumab versus 3%
in the placebo group (Table 3).7 One case of anaphylaxis
(1/1,434) was reported by a CD patient during the second
infusion which was managed with discontinuation of infusion and treatment with antihistamine and IV hydrocortisone.
Serious infections were more common in CD patients than
UC patients, and anal abscesses were the most frequently
reported serious adverse reaction in CD patients.7 There was
no increased rate of serious infections or significant changes
in laboratory values (ie, liver function test or hematological
test) in the treatment group.
Additionally, data regarding the safety of vedolizumab
come from a recent study by Loftus et al using the GEMINI 1
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Table 3 Adverse reactions in vedolizumab-treated patients and
in placebo patients
Adverse effects

Vedolizumab

Placebo

Nasopharyngitis
Headache
Arthralgia
Nausea
Pyrexia
Upper respiratory tract infection
Fatigue
Cough
Bronchitis
Influenza
Back pain
Rash
Pruritus
Sinusitis
Oropharyngeal pain
Pain in extremities

13%
12%
12%
9%
9%
7%
6%
5%
4%
4%
4%
3%
3%
3%
3%
3%

7%
11%
10%
8%
7%
6%
3%
3%
3%
2%
3%
2%
1%
1%
1%
1%

and 2 database. They showed that the infectious AE (ie,
nasopharyngitis, urinary tract infection) and infection serious
AE (ie, abscess, sepsis) profiles were similar among patients
(both UC and CD) who received vedolizumab monotherapy
and those who received vedolizumab with concomitant steroids and/or immunomodulators. Compared with placebo,
vedolizumab generally led to similar rates of infection, with
the exception of nasopharyngitis which was less common in
placebo group.7
Other integrin inhibitors, such as natalizumab (only
approved for CD), lack specificity for immunosuppression
and can subsequently affect immunomodulation in the brain.
Their immunosuppressive effect on the brain can lead to
progressive multifocal leukoencephalopathy (PML) in rare
cases. PML is a rare and fatal demyelinating disease of the
brain caused by reactivation of JC virus; this occurs due to
the nonspecific α4 inhibitory effects of natalizumab.8
As of June 2013, 3,129 patients have been treated with
vedolizumab. It is estimated that six to seven cases would have
been seen in the vedolizumab group, if the risk was similar to
those receiving natalizumab (1 case in 500 patients).2 However, no cases have been reported.2,5 Govani et al described the
rule of three to assess with a 95% CI the upper bound of likelihood (=3/n) for PML to occur on anti-adhesion molecules. As
3,129 patients have been treated with vedolizumab with zero
events of PML, we can estimate that the risk of PML is zero,
with a 95% CI from 0% to 0.1% or 10/10,000.20 Given that the
risk of PML in natalizumab-treated patients was increased after
2 years of exposure, we can estimate the risk of PML in those
exposed to vedolizumab for 2 years. Sands et al reported that
995 patients have been treated with vedolizumab for 2 years.
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Therefore, the estimated risk of PML after 2 years of vedolizumab treatment is zero, with a 95% CI from 0% to 0.3%
or 30/10,000 patients exposed for 2 years.2 If the sample size
increases without any PML events, we can more accurately
estimate a near 0% risk of developing PML.
Malignancies were reported among 0.4% of patients treated
with vedolizumab, including patients with colon cancer (n=2),
transitional cell carcinoma (n=1), breast cancer (n=1), carcinoid
tumor of the appendix (n=1), and squamous cell carcinoma
(n=1). Malignancy was reported in only one of 297 (0.3%)
patients treated with placebo (squamous cell carcinoma).7
While expert consensus recommends avoiding anti-TNF exposure for 5 years after treatment of a malignancy,21 it is not yet
clear if vedolizumab should abide by the same rule of thumb.
Long-term complications such as serious malignancies and
infections are also associated with the use of anti-TNF agents
and immunomodulators. A meta-analysis suggested that patients
receiving immunomodulators for the treatment of IBD have a
lymphoma risk of 0.012% (approximately fourfold higher;
3/100,000 average population → 12/100,000 patients). Patients
receiving anti-TNF agents have a 0.059% (approximately
threefold higher) risk of non-Hodgkin’s lymphoma (NHL),
with scattered case reports of a rare NHL (hepatosplenic T-cell
lymphoma) with the use of azathioprine–anti-TNF combination.
This has not been documented with the use of vedolizumab
alone. The risk of infection with anti-TNF agents is reported to
occur in 3.6% of patients versus 1.7% of controls.22
In our single-center experience of vedolizumab treatment
in ten patients for UC and CD, two patients experienced possibly drug-related adverse reactions. A 59-year-old man with
fistulizing CD who had failed multiple anti-TNF agents was
treated with vedolizumab. After the second loading dose at
week 2, he experienced painful large upper body lymphadenopathy. The patient was hospitalized, and serological testing
for HIV, Epstein-Barr virus, cytomegalovirus, and hepatitis
was negative. The patient was treated symptomatically with
IV hydration and pain management with complete resolution
of lymphadenopathy after 1 day. Vedolizumab was resumed,
and lymphadenopathy had not recurred during 3 months of
follow-up. A second patient, 66-year-old female with UC
and poor prior response to thiopurines and anti-TNF therapy,
was admitted with acute appendicitis 1 day following second
vedolizumab loading dose. She underwent appendectomy with
no further sequela and is currently receiving vedolizumab as
maintenance therapy and has achieved good clinical response.
Given the mechanism of action of vedolizumab, it is plausible
that it may make patients more susceptible to gastrointestinal
infections. To our knowledge, there have been no other reported
cases of appendicitis or transient lymphadenopathy.
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Of note, while the safety profile of vedolizumab appears
to be favorable in clinical studies, it should be a caveat that
this drug is still relatively new. Longer clinical data are still
needed to evaluate other unknown potential adverse effects,
such as in our two patients. While the absolute rate of these
events remains low, it should be weighed against the substantial benefits associated with treatment.

Vedolizumab versus other biological
agents
Currently, there are no head-to-head trials between various
biological agents assessing their efficacy and safety in the
management of the UC, thus making it difficult for the treating
physician to choose the “right” biological agent for individual
patients. The best evidence to date comes from the systematic
review and network meta-analysis done by Danese et al. Their
study included the randomized controlled trials (RCTs) assessing the efficacy of four biological agents currently available
for the management of UC – IFX, adalimumab, golimumab,
and vedolizumab. It is important to note that they excluded
patients previously exposed to biologics in their analysis. All
four biological agents were superior to placebo in inducing
clinical response, remission, and mucosal healing (ten RCTs,
2,282 biological-naïve patients). IFX was superior to adalimumab in inducing clinical response (odds ratio 2.79, 95% CI
0.95–8.83). Though none of the other comparisons between
the four agents reached statistical significance, the study did
demonstrate that IFX had the strongest data for induction
therapy in UC followed by vedolizumab, golimumab, and
adalimumab.23 Given the differences in patients, recruitment
criteria, definitions of response, and remission between the
trials, the findings may not reflect the induction results of a
true head-to-head study of these agents.
For assessing the efficacy of the four biologics in maintenance therapy, six RCTs were included (1,502 biologicalnaïve patients). Again, all the four biological agents were
superior to placebo in the maintenance of clinical response,
remission, and mucosal healing. The authors did not compare between the four biologics because of the difference in
the study designs of the maintenance-of-remission trials.23

Patient-focused perspectives such
as quality of life, patient satisfaction,
and acceptability
Since current treatments for UC are used to control inflammation, rather than provide a cure, maximizing the patients’
quality of life is an important goal.
Studies by Feagan et al showed an improvement in the
mean IBD quality-of-life questionnaire (IBDQ) scores, which
Therapeutics and Clinical Risk Management 2015:11
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Abbreviations: TNF, tumor necrosis factor; F, female; UC, ulcerative colitis; M, male; N/A, not available; IC, indeterminate colitis; CD, Crohn’s disease.

Yes
Yes; 100%
No
Yes
6 months
9 months
Yes
Yes
CD
CD
M/37
F/25
Patient 9
Patient 10

M/71
M/45
M/27
F/47
F/23
M/23
M/52
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8

UC
UC
IC
IC
IC/CD
CD
CD

Yes
Yes
Yes
Yes
Yes
Yes
Yes

14 months
7 months
11 months
3 months
7 months
5 months
6 months

Yes
No
Yes
No
No
Yes
No

N/A
No
N/A
Yes
Yes
N/A
Yes

Nausea, acute appendicitis
Status post appendectomy
None
None
None
None
Fatigue
None
Transient painful
lymphadenopathy
None
None
Yes
No
10 months
Yes
F/65
Patient 1

UC

Potentially drug-related
adverse event
Clinical improvement
by treating physician
Clinical remission by
treating physician
Duration of vedolizumab
treatment
Prior failure
to anti-TNF
Disease
Sex/age

Vedolizumab shows promise in the future of managing
moderate-to-severe UC.
As we gain more experience, the inevitable question about
the positioning of vedolizumab in the treatment algorithm
will arise – will it remain a second-line agent once one or even
two anti-TNF agents have failed, or whether vedolizumab in
moderate-to-severe UC may be considered a first-line therapy

Patient

Conclusion and place in therapy

Table 4 Experience with vedolizumab of our patients

suggest an improved global quality of life in terms of their
underlying disease. GEMINI 1 study showed a mean 20%
improvement in the IBDQ at week 6 in the vedolizumab
group compared to placebo. Furthermore, in the study group
that had treatment extended to 52 weeks, there was further
improvement in the IBDQ scores at 52 weeks compared to
30 weeks. This is conceivable as the clinical remission rates
increased from 16.9% at week 6 to 41.8% at week 52.24 The
time to clinical response suggest that vedolizumab, unlike
anti-TNF agents, may not demonstrate an immediate effect in
clinical symptoms. Sands et al demonstrated that the effects
of vedolizumab on clinical remission may not become evident
until between weeks 6 and 10 among CD patients. Patients
should be counseled on this prior to initiating treatment.
Patient acceptability is directly related to the adverse
effect profile. There is no significant difference in adverse
effects between vedolizumab and placebo, except for upper
respiratory tract infections. In our experience, patients have
a very favorable acceptance to the drug, but these patients
were often doing poorly on anti-TNF or combination therapy
at baseline. At our institution, even the two patients (out
of the ten exposed) who experienced potentially related
adverse drug reactions elected to continue therapy with vedolizumab. Table 4 details our institutional experience using
vedolizumab since it became available in July 2014.
There are several limitations to vedolizumab therapy. It
has to be administered intravenously. In contrast, subcutaneous biological (like adalimumab and golimumab) can be
administered at home by self-injection. Another major limitation is cost. A study by Liu et al showed that adalimumab
would cost much less than vedolizumab per responder and
remitter at 1 year in IBD patients (both UC and CD combined). Adalimumab cost at 1 year per responder and remitter
was $197,902 and $197,874, respectively. The cost of vedolizumab at 1 year per responder and remitter was $406,629
and $336,332, respectively.25 Given its short experience in
“real life”, the probability that IFX has the most potency in UC
induction, a potentially slower time to clinical improvement,
and higher payor costs, vedolizumab is currently reserved for
those having failed one anti-TNF therapy at our institution.
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in specific circumstances. Industry is unlikely to conduct
head-to-head studies, so we will need to look at how the drug
will be adopted by clinicians in the years to come.
Further research to determine if there are phenotypic,
genetic, or biomarker predictors of response would be beneficial
in choosing an agent, particularly to reduce cost and improve
patient outcomes. Additionally, no data are currently available
regarding combination use of immunomodulators and vedolizumab or anti-TNF agents and vedolizumab in terms of safety
and efficacy. The combination use of these medications needs
to be studied, as we have learned from the SONIC trial that
combination therapy with anti-TNF plus thiopurines was more
likely to induce a corticosteroid-free clinical remission.26
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